Vitiligo

STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

Retrieved on: 
Thursday, March 7, 2024

The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

Key Points: 
  • The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.
  • “Our focus extends beyond merely seeking expanded insurance coverage; we're advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments," stated Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA.
  • Over the past two months, as part of this advocacy initiative STRATA has sent over 1,000 legislative support letters to congressional and senate delegates on behalf of its patients.
  • Phototherapy has been the cornerstone of therapy for decades and remains an indispensable part of current therapy.

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

Retrieved on: 
Tuesday, March 5, 2024

The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.

Key Points: 
  • The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.
  • Philanthropy is central to the work of Lady Gaga and Michael Polansky, Sean Parker and Alexandra Parker.
  • At the event in Malibu, CLINUVEL announced the Photomedicine Foundation, which will count Mr Polansky as a trustee.
  • CLINUVEL is grateful to have their support as we translate our pharmaceutical technology into PhotoCosmetics and give back to underserved communities.

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024

“We have made excellent progress with our VYN201 program and remain on track to initiate a Phase 2b trial in nonsegmental vitiligo next quarter.

Key Points: 
  • “We have made excellent progress with our VYN201 program and remain on track to initiate a Phase 2b trial in nonsegmental vitiligo next quarter.
  • Trial startup activities are ongoing with patient enrollment expected to begin in the second quarter of 2024.
  • VYNE recently completed this study and achieved preliminary results consistent with its expectations at the outset of the study.
  • VYNE plans to submit the requested nonclinical information to the FDA by the end of the first quarter of 2024.

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Retrieved on: 
Tuesday, February 27, 2024

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201

Key Points: 
  • Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201
    BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentation featuring positive data from the Phase 1b trial of VYN201 in vitiligo at the 2024 Global Vitiligo Foundation Annual Scientific Symposium taking place in San Diego on March 7, 2024.
  • “We are pleased to have this opportunity to present the data from our Phase 1b trial with the vitiligo community at the Global Vitiligo Foundation Annual Scientific Symposium,” said Dr. Iain Stuart, Chief Scientific Officer of VYNE.
  • “The positive clinical data from the Phase 1b trial supports the advancement of VYN201 into a Phase 2b trial that we expect to initiate next quarter.”
    A Phase 1 Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of a Topical Pan-BD BET Inhibitor (VYN201) in Subjects with Active Non-Segmental Vitiligo (session #4)

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 4, 2024

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
  • “We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.

Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024

Retrieved on: 
Friday, March 8, 2024

DURHAM, N.C., March 8, 2024 /PRNewswire/ -- New patient-reported outcomes data presented at AAD 2024 from Target RWE's TARGET-DERM AA registry confirms the high unmet need and significant disease burden in patients with moderate to severe alopecia areata (AA). TARGET-DERM is the largest and most comprehensive longitudinal RWE study observing patients with immune-mediated inflammatory skin conditions in the United States.

Key Points: 
  • Patients with AA have a high unmet medical need due to comorbid conditions and high impact on quality of life.
  • The most common comorbid conditions associated with AA include vitiligo, atopic dermatitis (eczema), Hashimoto's thyroiditis, psoriasis, and systemic lupus erythematosus.
  • TARGET-DERM AA is distinctively positioned to address real-world access to care, disease progression, diagnosis, and treatment in patients with moderate to severe AA.
  • "What's important about our data presented at AAD and TARGET-DERM AA is that we are gaining insights on the impact of the disease.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Retrieved on: 
Wednesday, January 10, 2024

The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.

Key Points: 
  • The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.
  • Positive clinical data from the Phase 1b trial were announced in October 2023.
  • One lesion, selected for treatment with VYN201, had skin tissue biopsies taken prior to first application of VYN201 and after 8 weeks of treatment.
  • “We are encouraged by these new biomarker data from the Phase 1b trial for VYN201, building on our recently announced positive clinical results,” said David Domzalski, President and CEO of VYNE.